GB9325445D0
(en)
|
1993-12-13 |
1994-02-16 |
Cortecs Ltd |
Pharmaceutical formulations
|
GB9403855D0
(en)
*
|
1994-03-01 |
1994-04-20 |
Scotia Holdings Plc |
Fatty acid derivatives
|
EP0711503A3
(en)
*
|
1994-11-14 |
1997-11-26 |
Scotia Holdings Plc |
Milk fortified with GLA and/or DGLA
|
US5804210A
(en)
*
|
1996-08-07 |
1998-09-08 |
Wisconsin Alumni Research Foundation |
Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
|
GB9617847D0
(en)
|
1996-08-27 |
1996-10-09 |
Scotia Holdings Plc |
Fatty acid treatment
|
AU8857298A
(en)
*
|
1997-07-16 |
1999-02-10 |
Societe Des Produits Nestle S.A. |
Method for prophylaxis or treatment of bone density loss
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
US6479545B1
(en)
*
|
1999-09-30 |
2002-11-12 |
Drugtech Corporation |
Formulation for menopausal women
|
EG22407A
(en)
*
|
2000-02-17 |
2003-01-29 |
Iams Company |
Method for improving bone modeling and chondrocyte functioning in growing canines
|
US7635692B2
(en)
|
2001-03-15 |
2009-12-22 |
Dsm Ip Assets B.V. |
Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
|
CA2442692A1
(en)
*
|
2001-03-30 |
2002-10-10 |
The Nisshin Oillio, Ltd. |
Bone metabolism improving agents
|
US7098352B2
(en)
*
|
2001-11-16 |
2006-08-29 |
Virtus Nutrition Llc |
Calcium salt saponification of polyunsaturated oils
|
WO2005063231A2
(en)
*
|
2003-12-31 |
2005-07-14 |
Igennus Limited |
Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
|
EP1765964A4
(en)
*
|
2004-04-30 |
2007-11-07 |
|
Polyunsaturated fatty acid monovalent and divalent metal salt synthesis
|
EP1968402A2
(en)
*
|
2005-10-07 |
2008-09-17 |
Ocean Nutrition Canada Limited |
Salts of fatty acids and methods of making and using thereof
|
DE102007022694A1
(en)
*
|
2007-05-11 |
2008-11-13 |
Humana Milchunion Eg |
Milk fat milk protein composition to improve calcium absorption
|
DE102007039310A1
(en)
*
|
2007-08-13 |
2009-02-19 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Composition for the prophylaxis and treatment of osteoporosis
|
US8343753B2
(en)
*
|
2007-11-01 |
2013-01-01 |
Wake Forest University School Of Medicine |
Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
|
EP3578177A1
(en)
|
2008-09-02 |
2019-12-11 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
KR20140007973A
(en)
|
2009-02-10 |
2014-01-20 |
아마린 파마, 인크. |
Methods of treating hypertriglyceridemia
|
NZ624963A
(en)
|
2009-04-29 |
2016-07-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
BRPI1011876B1
(en)
|
2009-04-29 |
2020-03-31 |
Amarin Pharma, Inc. |
STABLE PHARMACEUTICAL COMPOSITIONS UNDERSTANDING EICOSAPENTAENOIC ETHYLACID (ETHYL-EPA) AND USE OF THE SAME TO TREAT OR PREVENT A CARDIOVASCULAR DISEASE
|
GB0907413D0
(en)
|
2009-04-29 |
2009-06-10 |
Equateq Ltd |
Novel methods
|
CN102625847A
(en)
|
2009-06-15 |
2012-08-01 |
阿马里纳制药公司 |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
AU2010298222B2
(en)
|
2009-09-23 |
2017-01-05 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
CA3043081C
(en)
*
|
2010-03-04 |
2020-02-11 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US8178707B2
(en)
|
2010-03-25 |
2012-05-15 |
Jost Chemical Company |
Co-precipitated salts of fatty acids
|
CN101978949A
(en)
*
|
2010-11-16 |
2011-02-23 |
王京南 |
Gamma-linolenate fat emulsion intravenous injection and preparation method thereof
|
AU2011336856A1
(en)
|
2010-11-29 |
2013-07-04 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US8293790B2
(en)
|
2011-10-19 |
2012-10-23 |
Dignity Sciences Limited |
Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
ES2891473T3
(en)
|
2012-01-06 |
2022-01-28 |
Amarin Pharmaceuticals Ie Ltd |
Compositions and methods for reducing high sensitivity levels (hs-CRP) in a subject
|
SG10201913645RA
(en)
|
2012-06-29 |
2020-03-30 |
Amarin Pharmaceuticals Ie Ltd |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US8728546B1
(en)
|
2013-03-15 |
2014-05-20 |
Swing Aerobics Licensing, Inc. |
Medicament for treatment of cancer, cardiovascular diseases and inflammation
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
KR102391827B1
(en)
|
2014-06-04 |
2022-04-27 |
디에스 바이오파마 리미티드 |
Pharmaceutical compositions comprising dgla and use of same
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
MX2018014140A
(en)
*
|
2016-06-01 |
2019-02-25 |
Nestec Sa |
Composition for use in the prophylaxis of allergic disease.
|
US10966951B2
(en)
|
2017-05-19 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
MA51765A
(en)
|
2018-09-24 |
2020-12-16 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
|
US20210315851A1
(en)
|
2020-04-03 |
2021-10-14 |
Afimmune Limited |
Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
|
US11986452B2
(en)
|
2021-04-21 |
2024-05-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|